Healthcare company Takeda (TSE: 4502) (NYSE: TAK) on Wednesday reported detailed results from its pivotal Phase 2/3 IgGNITE trial of investigational TAK-881 for primary immunodeficiency disease (PID), demonstrating comparable pharmacokinetics to HYQVIA in patients aged 16 and over. The findings were presented at the European Society for Immunodeficiencies 2026 meeting in Maastricht.
TAK-881 delivered equivalent immunoglobulin dosing in 50% less volume, reducing median infusion times by 56.2 minutes with one infusion site and 27.7 minutes with two sites compared with HYQVIA. The therapy is designed to support dosing every three to four weeks, potentially reducing treatment burden for patients requiring long-term immunoglobulin replacement.
In descriptive analyses, infection outcomes and safety and tolerability were comparable to HYQVIA, with no new safety signals identified. Takeda is continuing long-term safety evaluation through an extension study.
The company expects to submit regulatory applications for TAK-881 in the US, European Union and Japan during fiscal year 2026.
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m
UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment
Valneva reports positive Phase 2 results for tetravalent Shigella vaccine candidate
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease